Healthcare technology continues to evolve as companies look for better ways to improve patient care. While modern medicines have transformed the treatment of many chronic diseases, the method used to deliver those medicines often remains a challenge. Millions of patients around the world depend on regular injections for conditions such as autoimmune disorders, inflammatory diseases, and other long-term health conditions. For many of them, needles create discomfort, anxiety, and stress that can affect their treatment experience.
Portal Instruments is working to change that reality. The company has developed an innovative smart drug delivery platform designed to make injectable therapies faster, easier, and more comfortable for patients. By combining needle-free technology with digital connectivity and reusable device design, Portal Instruments is helping shape the future of drug delivery.
Founded in 2012 as a spinout from the Massachusetts Institute of Technology (MIT), Portal Instruments has spent more than a decade developing solutions that address some of the biggest challenges in injectable medicine. Today, the company stands among the innovators working to improve how patients receive life-changing therapies.
Smart Drug Delivery Systems Are Changing Modern Healthcare
The healthcare industry increasingly relies on smart drug delivery systems to improve treatment outcomes and patient experiences. These systems go beyond traditional syringes and injection devices by incorporating advanced technologies that support precision, convenience, and patient engagement.
Smart drug delivery devices can help patients follow treatment schedules, monitor medication use, and share important information with healthcare providers. They are designed to simplify treatment routines and reduce barriers that often prevent patients from following prescribed therapies.
As biologic medicines become more common, pharmaceutical companies are looking for delivery technologies that can support these advanced treatments while improving the patient experience. This growing demand has created opportunities for innovative companies like Portal Instruments to introduce new approaches to drug delivery.
Portal Instruments Began with a Vision to Eliminate Needle Anxiety
Portal Instruments was established in 2012 to commercialize a breakthrough technology developed at MIT. The company emerged from research led by Dr. Ian Hunter, a professor known for his work in bioinstrumentation and medical technology.
The idea behind Portal Instruments was straightforward but ambitious. The founders wanted to create a better way for patients to receive injectable medicines. Traditional injections have remained largely unchanged for decades, despite advances in pharmaceutical science. The company believed that drug delivery should evolve alongside the medicines themselves.
This vision led to the development of a platform that uses a high-speed liquid jet instead of a conventional needle. Rather than piercing the skin with a metal needle, the device delivers medication through a precisely controlled stream of liquid. The technology represents a different approach to injection therapy and addresses one of the most common concerns among patients who require regular injections.
The Company’s Needle-Free Technology Offers a New Approach
Portal Instruments has developed a needle-free delivery platform that uses pressure-driven technology to administer medication. The system creates a narrow stream of liquid that passes through the skin and delivers medicine into the body without the use of a traditional needle.
The platform was designed to provide accurate and consistent drug delivery while reducing many of the concerns associated with standard injections. Because the technology does not rely on a conventional needle, it offers an alternative for patients who experience anxiety about self-injection. The company has focused on maintaining precision throughout the delivery process. The system is designed to ensure that patients receive the intended dosage while supporting the requirements of modern biologic medicines.
As pharmaceutical companies continue developing advanced therapies, drug delivery technologies must adapt to support these new treatments. Portal Instruments created its platform with this future in mind, aiming to provide flexibility and reliability for a wide range of injectable medications.
Connectivity Makes Drug Delivery Smarter
One of the defining features of smart drug delivery systems is their ability to connect patients with healthcare information in real time. Portal Instruments has integrated connectivity into its platform to support treatment management and patient engagement. The company’s devices can connect with digital applications that help patients track their medication schedules. These applications can provide reminders and record treatment information automatically, reducing the need for manual tracking.
For patients managing chronic conditions, maintaining a consistent treatment routine is essential. Missed doses can affect outcomes and make disease management more difficult. Connected drug delivery systems help address this challenge by creating a more organized and user-friendly treatment experience.
The data generated by connected devices can also provide valuable insights for healthcare providers. Access to treatment information allows care teams to better understand patient adherence and identify potential issues that may require attention. This combination of physical drug delivery and digital support reflects the broader movement toward connected healthcare technologies.
Improving the Experience for Patients
Patient experience has become a major focus across the healthcare industry. Medical treatments are more effective when patients feel comfortable and confident using them. Portal Instruments has built its technology around this principle. Many patients who require regular injections struggle with needle anxiety. Some postpone treatment because they fear the injection process, while others find self-administration stressful even after years of therapy.
Portal Instruments developed its needle-free technology to help reduce these concerns. By removing the traditional needle from the injection process, the company aims to create a more comfortable and approachable experience. The company’s vision extends beyond simply delivering medication. It focuses on helping patients feel more in control of their treatment journey. This patient-centered approach has become increasingly important as healthcare systems emphasize quality of life alongside clinical outcomes. For individuals who rely on injectable therapies, even small improvements in comfort and convenience can make a meaningful difference in daily life.
Sustainability Plays an Important Role in Product Development
Healthcare organizations around the world are paying greater attention to sustainability. Medical devices often generate significant waste, particularly when they are designed for single use. Portal Instruments has incorporated reusable design principles into its drug delivery platform. By separating reusable electronic components from disposable medication components, the company seeks to reduce waste while maintaining performance and safety.
Reusable systems may help reduce material waste compared with fully disposable drug delivery devices. This approach aligns with broader industry efforts to develop more sustainable healthcare solutions while maintaining product quality and patient safety. As sustainability becomes a larger priority across the medical industry, companies that integrate environmentally conscious design into their products are likely to play an important role in future healthcare innovation. Portal Instruments recognizes this trend and has positioned sustainability as one of the key considerations in its product strategy.
Strategic Partnerships Have Strengthened the Company’s Growth
Partnerships with established healthcare organizations have helped Portal Instruments accelerate the development and commercialization of its technology. One notable collaboration involves Takeda Pharmaceutical Company. The partnership focuses on exploring how Portal’s needle-free delivery technology can be used with biologic therapies. The collaboration reflects growing interest from pharmaceutical companies in alternative methods of drug administration that improve convenience and patient experience.
Portal Instruments also entered into a strategic relationship with Gerresheimer, a global provider of healthcare solutions and drug delivery systems. In 2022, Gerresheimer acquired a minority stake in Portal Instruments and gained representation on the company’s Board of Directors.
The partnership combines Portal’s innovative delivery technology with Gerresheimer’s expertise in healthcare manufacturing and drug delivery solutions. Together, the companies are working to support the commercialization of advanced injector platforms for pharmaceutical partners. These collaborations demonstrate industry confidence in Portal Instruments and its long-term vision for the future of drug delivery.
Funding Helped Turn Innovation into Reality
Bringing a new medical technology to market requires significant investment. Portal Instruments has secured funding from respected investors who recognized the potential of its platform.
In 2014, the company completed an $11 million Series A financing round. The investment included participation from Sanofi through its Sunrise initiative, PBJ Capital, and a major U.S. medical device company. The funding provided resources to continue product development and advance commercialization efforts.
The following year, Portal Instruments completed a $25 million Series B financing round led by 5 AM Ventures, with participation from existing investors. This investment supported the company’s continued growth and strengthened its position within the drug delivery sector. These funding milestones played a critical role in helping Portal Instruments move from academic research to commercial development.
Patrick Anquetil Leads the Company with Scientific and Business Expertise
Dr. Patrick Anquetil serves as the Founder and Chief Executive Officer of Portal Instruments. His educational background and entrepreneurial experience have been central to the company’s development. Patrick Anquetil studied engineering before continuing his academic and research work at MIT. He later earned a Ph.D. in Bio-Instrumentation from the Massachusetts Institute of Technology and completed an MBA at Harvard Business School.
Before launching Portal Instruments, he founded and helped build several healthcare technology companies. These experiences gave him firsthand knowledge of the challenges involved in transforming scientific discoveries into commercially successful businesses. At Portal Instruments, Anquetil has guided the company from its early stages as an MIT spinout to a recognized innovator in smart drug delivery technology. He has led fundraising efforts, established strategic partnerships, and overseen the development of the company’s needle-free platform.
His leadership has focused on one clear objective: improving the way patients receive injectable medicines. Working closely with MIT inventor Dr. Ian Hunter and the company’s engineering teams, Anquetil has helped turn an academic concept into a technology platform with global potential. His combination of scientific knowledge, business leadership, and entrepreneurial vision continues to influence the company’s growth and long-term strategy.
Looking Toward the Future of Drug Delivery
The future of healthcare will likely involve greater personalization, increased connectivity, and more patient-centered treatment experiences. Drug delivery systems will play an important role in that transformation. Portal Instruments is positioning itself at the intersection of these trends. The company’s needle-free technology addresses patient comfort, while its connected platform supports better treatment management and healthcare engagement.
As pharmaceutical companies continue developing new biologic therapies, demand for advanced delivery technologies is expected to increase. Patients, healthcare providers, and pharmaceutical manufacturers all benefit when treatments become easier to administer and manage. Portal Instruments has built its business around the belief that innovation should improve both clinical outcomes and patient experiences. Through its focus on needle-free delivery, digital connectivity, and sustainable design, the company is helping redefine how injectable medicines are delivered.
More than a decade after its founding, Portal Instruments continues to pursue its vision of transforming drug delivery. Its work demonstrates that healthcare innovation is not only about creating new medicines but also about improving the way those medicines reach the people who depend on them. By addressing long-standing challenges associated with injections, the company is contributing to a future where treatment becomes more comfortable, more connected, and more accessible for patients around the world.
